Indegene Limited has issued a formal response to the BSE regarding inquiries about increased trading volume in the company's securities. The clarification, dated March 16, 2026, addresses the exchange's concerns about significant movements in both price and trading volume.

Company's Official Response

In response to BSE's communication reference L/SURV/ONL/PV/SG/ 2025-2026 / 977, Indegene confirmed that no undisclosed material events are pending that could significantly impact the stock's performance. The company stated that recent market movements appear to be aligned with prevailing market conditions and overall investor sentiment.

Regulatory Compliance Commitment

The company emphasized its dedication to maintaining transparent and timely disclosures in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Indegene assured that any material developments will be communicated following applicable regulatory requirements.

Market Movement Attribution

Indegene attributed the recent volatility and trading activity to broader market dynamics rather than company-specific factors. The response indicates that the price and volume movements are consistent with general market conditions and investor behavior patterns.

The formal communication was digitally signed by Company Secretary and Compliance Officer Srishti Ramesh Kaushik on March 16, 2026, at 12:46:47 +05'30', ensuring proper documentation and regulatory compliance.

Indegene Limited has announced a scheduled investor/analyst meeting as part of its regulatory compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The pharmaceutical services company informed both BSE and NSE about the upcoming engagement through an official communication dated March 13, 2026.

Meeting Details

The company has scheduled a focused investor interaction for March 18, 2026, with specific details outlined for stakeholder transparency.

Regulatory Compliance

The meeting notification follows standard regulatory protocols under SEBI guidelines. Company Secretary and Compliance Officer Srishti Ramesh Kaushik signed the official communication, emphasizing the company's commitment to transparency and regulatory adherence.

Key compliance aspects include:

• No unpublished price sensitive information will be shared during the meeting
• Meeting details made available on the company website at www.indogene.com
• Schedule subject to change due to exigencies
• Proper notification to both stock exchanges

Company Information

Indegene Limited operates from its headquarters at Manyata Embassy Business Park in Bengaluru, Karnataka. The company maintains its listing on both major Indian stock exchanges with scrip code 544172 on BSE and trading symbol INDGN on NSE. The formal communication ensures all stakeholders remain informed about the company's investor engagement activities as required under current listing regulations.